Skip to content
Sunday, November 15, 2026
Capital Jackpot

Individuals Coming Off Weight-Loss Injections Regain Weight at a Quadrupled Rate Compared to People Using Diet and Exercise

Illustration of pharmaceutical syringe and scale
Obesity treatment often requires ongoing approaches.

Fresh analysis suggests that people who come off popular GLP-1 drugs like Wegovy and Mounjaro can put back on shed pounds much more quickly than those who end conventional lifestyle programs.

Findings released in a leading health publication shows that while obese people often shed about a fifth of their body weight while using the jabs, the mass returns at an average rate of nearly a kilo each month once they quit.

"Individuals using these treatments must be informed of the potential of rapid weight regain when the treatment ends," warns lead investigator Dr. Susan Jebb.

Such speed of recovery suggests a reversion to pre-treatment weight in about a year and a half.

Analyzing Treatments

The analysis, which looked at 37 of trials involving over 9,000 of participants, compared the results of GLP-1 agonists with conventional dieting.

Scientists point out that people who lose weight through lifestyle changes alone typically see a less rapid weight regain—approximately 0.1 kg a month—once they finish.

The Reason for the Rapid Regain

Doctors believe the mode of action of the drugs is key to understanding the accelerated regain.

These medications mimic a natural hormone called GLP-1, which helps regulate feelings of fullness.

"Long-term administration of GLP-1 concentrations several times higher than the body's typical production could lead to the system to produce less of its endogenous GLP-1, and could reduce sensitivity to its actions," noted Dr. Adam Collins, a dietetics specialist.

"Withdrawal of this medication leads to hunger is unsuppressed, making overeating far more likely."

An Ongoing Disease?

Medical guidelines recommend the jabs for individuals with weight-linked health risks, alongside recommended diet and exercise modifications.

Many experts say that, considering the high risk of relapse, the therapy might need to be long-term.

This view is supported by drug manufacturers, who state that the findings "underscore the persistent nature of excess weight," comparing it to managing diseases like diabetes.

User Testimonies

Individuals who have come off the medication report a sudden return of cravings.

"I experienced something activating and I was suddenly starving," said an individual.

The struggle is exacerbated if patients have not adopted lasting dietary or behavioural modifications during therapy.

Widespread Use

Recent estimates indicate that a significant number of people in the UK have tried weight-loss jabs in the past year, with interest remaining high.

  • Adoption is more common among women compared to males.
  • The 40s and 50s age group shows the highest level of interest.
  • Many obtain the medications through private healthcare rather than public health services.

Finally, experts caution that while GLP-1 drugs are powerful tools for weight loss, they are not a standalone cure and long-term success relies on combined behavioural support.

AH
About the author

Andrew Hall

A seasoned financial analyst with over 15 years of experience in UK markets, specializing in investment strategies and economic forecasting.

Capital Jackpot

Type to search articles.